Spero Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Spero Therapeutics, Inc. (SPRO) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $1.29 per share for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-13.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2023-11-13
- Spero Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-03-31 was $1.29, a 83.79% decline year-over-year.
- Spero Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2022-03-31 was $7.96, a 45.37% decline year-over-year.
- Spero Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2021-03-31 was $14.57, a 128.37% increase year-over-year.
- Spero Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2020-03-31 was $6.38, a 42.09% increase year-over-year.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month |
|---|---|---|---|
| 2023-09-30 | $1.29 10-Q · filed 2023-11-13 | ||
| 2023-06-30 | $1.29 10-Q · filed 2023-08-10 | ||
| 2023-03-31 | $1.29 10-Q · filed 2023-05-11 | ||
| 2022-09-30 | $7.94 10-Q · filed 2023-11-13 | ||
| 2022-06-30 | $7.95 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | $7.96 10-Q · filed 2023-05-11 | ||
| 2021-09-30 | $13.57 10-Q · filed 2022-11-14 | ||
| 2021-06-30 | $14.05 10-Q · filed 2022-08-10 | ||
| 2021-03-31 | $14.57 10-Q · filed 2022-05-16 | ||
| 2020-09-30 | $6.80 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | $6.70 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | $6.38 10-Q · filed 2021-05-06 | ||
| 2019-09-30 | $5.03 10-Q · filed 2020-11-05 | ||
| 2019-06-30 | $4.93 10-Q · filed 2020-08-06 | ||
| 2019-03-31 | $4.49 10-Q · filed 2020-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 |